Aminoadamantanes versus other antiviral drugs for chronic hepatitis C

  • Protocol
  • Intervention

Authors

  • Mieke H Lamers,

    Corresponding author
    1. Radboud University Medical Center Nijmegen, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands
    2. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, The Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author
  • Mark Broekman,

    1. Radboud University Medical Center Nijmegen, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands
    Search for more papers by this author
  • Joost PH Drenth,

    1. Radboud University Medical Center Nijmegen, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands
    Search for more papers by this author
  • Christian Gluud

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, The Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To explore the beneficial and harmful effects of aminoadamantanes compared with other antiviral drugs for patients with chronic hepatitis C virus infection in a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.